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Abstract. The Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) family mediates parasite seques-
tration in small capillaries through tissue-specific cytoadherence. The best characterized of these proteins is VAR2CSA,
which is expressed on the surface of infected erythrocytes that bind to chondroitin sulfate in the placental matrix.
Antibodies to VAR2CSA prevent placental cytoadherence and protect against placental malaria. The size and complex-
ity of the VAR2CSA protein pose challenges for vaccine development, but smaller constitutive domains may be suitable
for subunit vaccine development. A protein microarray was printed to include five overlapping fragments of the 3D7
VAR2CSA extracellular region. Malian women with a history of at least one pregnancy had antibody recognition of four
of these fragments and had stronger reactivity against the two distal fragments than did nulliparous women, children, and
men from Mali, suggesting that the C-terminal extracellular VAR2CSA domains are a potential focus of protective
immunity. With carefully chosen sera from longitudinal studies of pregnant women, this approach has the potential to
identify seroreactive VAR2CSA domains associated with protective immunity against pregnancy-associated malaria.
INTRODUCTION
Plasmodium falciparum, the deadliest and most common
species of malaria in Africa, has the ability to adhere to capil-
lary beds due to proteins expressed on the surface of infected
red blood cells. During pregnancy, this sequestration of
infected erythrocytes and the ensuing inflammatory response
reduce placental blood flow and lead to fetal and maternal
compromise. Naturally acquired immunity to malaria develops
in childhood and appears, in part, to be related to the develop-
ment of antibodies to these malaria parasite surface antigens.
The var family of genes encodes one such set of antigens,
P. falciparum erythrocyte membrane protein 1 (PfEMP1),
which bind to endothelial receptors.1 Each parasite genome
carries about 60 var genes but expresses only one predomi-
nant PfEMP1 at a time, providing a large repertoire of surface
molecules believed to be important for immune evasion and
pathogenesis. In pregnant women, parasitized erythrocytes
expressing the PfEMP1 VAR2CSA bind to chondroitin sulfate
A (CSA) in the placental matrix,2–4 leading to chronic infection
and inflammation. Thus, although adults achieve a state of
semi-immunity in which they are protected from severe dis-
ease and death due to P. falciparum, pregnant women have an
increased vulnerability to infection, especially during their
first or second pregnancy, because they lack a protective
immune response to this antigen. With each pregnancy, women
develop antibodies that protect against placental adhesion
of infected erythrocytes and are associated with improved
birth outcomes.5
The size and complexity of the VAR2CSA protein pose
challenges for vaccine development, but smaller constitutive
domains may be suitable for a subunit vaccine targeted
against pregnancy-associated malaria. Studies attempting to
identify which of the seven constitutive extracellular
VAR2CSA domains are critical to the protective antibody
response have produced differing results,6,7 in part due to
different protein expression systems and serum sample com-
parisons. Current pregnancy-associated malaria vaccine devel-
opment efforts have focused on the first four extracellular
VAR2CSA domains, given their role in CSA binding.8–10
When probed with appropriately expressed VAR2CSA con-
stitutive domains, sera from women with at least one preg-
nancy should react to more VAR2CSA domains as well as
domains critical to the protective antibody response more
strongly than sera from nulliparous women, men, and chil-
dren. To determine whether such differential seroreactivity
of VAR2CSA fragments exists, reactivity to constitutive
domains of VAR2CSA was measured with a protein microar-
ray using sera from children, men, and women living in an
area with highly seasonal but intense malaria transmission in
Mali, west Africa.
MATERIALS ANDMETHODS
Serum samples were obtained from 75 children aged 1–
6 years and 77 adults, including 32 men and 45 women
enrolled in malaria vaccine trials conducted in Bandiagara,
Mali.11–13 Sixteen women reported that they were never preg-
nant, while the remaining 29 women had between one to nine
previous pregnancies, with a median of three pregnancies.
The median age of women was 27 years, while the median
age of men was 23 years. Sera from 11 malaria-naive U.S.
blood donors were used as controls. Vaccine trials were con-
ducted in compliance with the International Conference on
Harmonisation Good Clinical Practices, the Declaration of
Helsinki, and Malian regulatory requirements.
A protein microarray was designed to include five 3D7-
based VAR2CSA fragments (Figure 1). For simplicity,
PFL0030c_1, _2, _3, _4, and _5 are henceforth referred to as
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Fragments 1, 2, 3, 4, and 5, respectively. Start and endpoints of
constitutive VAR2CSA domains were based on a recent
reclassification of var domains.14 Each fragment was designed
to include two consecutive extracellular constitutive domains.
Array construction occurred as previously described, includ-
ing transcription and translation using a cell-free Escherichia
coli-based in vitro system,15–17 with the addition of the RTS
100 E. coli Disulfide kit (5 Prime, Gaithersburg, MD) to sup-
port disulfide bond formation. Protein microarray printing and
quality control protocols have been previously described.18
Arrays were probed with 2 mL of participant sera after a 1-hour
incubation with E. coli lysate to bind nonmalaria-specific anti-
bodies in each sample. Probing and scanning protocols have
been detailed elsewhere.18 After overnight antibody hybridiza-
tion at 4°C, arrays were washed, stained, and dried before scan-
ning with a microarray scanner (PerkinElmer, Waltham, MA).
Raw signal intensity was reduced by the mean of the “no-
DNA”-negative controls to determine fluorescence intensity.
Samples with negative fluorescence intensity were treated as
zero fluorescence intensity. “Recognition” of a VAR2CSA
fragment was defined as fluorescence intensity significantly
greater than that of the malaria-naı¨ve control group, based
on a two-sample Kolmogorov–Smirnov test. All other unmatched
fluorescence intensity comparisons between groups were like-
wise made with a two-sample Kolmogorov–Smirnov test.
These statistical analyses were performed using MYSTAT 12,
Version 12.02.00 (Systat Software, Inc., San Jose, CA). Multi-
variate analysis was conducted using linear regression model-
ing with SAS 9.3.
RESULTS
Women with at least one pregnancy had antibody recogni-
tion to four out of five VAR2CSA fragments (Fragment 1:
P = 0.002; Fragment 2: P = 0.004; Fragment 4: P < 0.001;
Fragment 5: P < 0.001; Figure 2). Men had antibody recogni-
tion to three VAR2CSA fragments (Fragment 1: P = 0.001;
Fragment 2: P < 0.001; Fragment 5: P = 0.003). Although some
men also reacted to Fragment 4, as a group, men did not
significantly recognize this fragment more than controls (P =
0.065). In contrast, nulliparous women and children did not
have antibody recognition to any VAR2CSA fragments. A
Figure 1. VAR2CSA fragments on the microarray included all seven extracellular domains of PFL0030c, the VAR2CSA in the 3D7 reference
genome of Plasmodium falciparum. Starting and ending amino acid positions are indicated below each fragment and domain.
Figure 2. Heat map of seroreactivity to five 3D7 VAR2CSA fragments, with each fragment separated by row. Each column displays the
profile of one serum sample. Grey color indicates no seroreactivity, black is low-to-moderate seroreactivity, and red denotes high seroreactivity to
probed fragments.
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few nulliparous women recognized Fragment 1 in particular,
but overall, they did not significantly recognize this fragment
more than controls (Fragment 1: P = 0.066). Fragment 3 was
not recognized by any group (P > 0.15).
Women with at least one pregnancy recognized two frag-
ments, Fragments 4 and 5, more strongly than any other
malaria-exposed groups (Figure 3), including nulliparous
women (Fragment 4: P = 0.004; Fragment 5: P = 0.002), men
(Fragment 4: P = 0.052; Fragment 5: P = 0.040), and children
(Fragment 4: P < 0.001; Fragment 5: P < 0.001). Amultivariable
linear regression model for predicting fluorescence intensity
found a significant association with numbers of pregnancies,
controlling for age, for both Fragment 4 (P = 0.02) and
Fragment 5 (P = 0.04), but not for other VAR2CSA frag-
ments (Fragment 1: P = 0.51; Fragment 2: P = 0.27; Fragment
3: P = 0.85). There was no association of fluorescence inten-
sity with age when controlling for numbers of pregnancies
(Fragment 1: P = 0.94; Fragment 2: P = 0.53; Fragment 3: P =
0.85; Fragment 4: P = 0.14; Fragment 5: P = 0.51).
All three groups of malaria-exposed adults had higher anti-
body recognition of Fragment 1 than did children (nulliparous
women: P = 0.045; women with at least one pregnancy:
P < 0.001; men: P < 0.001). Sera from the three groups of
adults did not differ in recognition of this fragment (women
with at least one pregnancy versus nulliparous women: P =
0.265; women with at least one pregnancy versus men: P =
0.737; nulliparous women versus men: P = 0.341).
In contrast to nulliparous women, women with at least one
pregnancy and men had higher antibody recognition of Frag-
ment 2 than did children (nulliparous women: P = 0.181;
women with at least one pregnancy: P = 0.004; men: P < 0.001).
DISCUSSION
A microarray with five 3D7 VAR2CSA fragments was
probed with sera from adults and children living in a malaria-
endemic region, revealing differential seroreactivity by age,
sex, and number of pregnancies. Sera from women with at
least one pregnancy recognized more VAR2CSA fragments
than sera from nulliparous women, men, and children. Sera
from multiparous women recognized the two C-terminal frag-
ments, Fragments 4 and 5, to a greater extent than sera from
any other group. Moreover, increased gravidity was associ-
ated with higher seroreactivity to these two fragments.
Fragments 4 and 5 together spanned the last three constitutive
domains of the extracellular portion of the 3D7 VAR2CSA,
and both fragments included the DBLepam5 domain. Higher
levels of antibodies against DBLepam5 have been found in
plasma from pregnant Senegalese women than in plasma
from men or nulligravid women.19 In Malawi, sera from
multigravid women recognized this domain more strongly
than sera from primigravid women.20 However, other studies
have not supported the finding of DBLepam5 as the
VAR2CSA domain primarily recognized by antibodies from
multigravid women. Antibodies to the DBLepam5 domain
have been detected in sera from young Tanzanian children21
and Colombian men and children.22 Antibody recognition of
other individual VAR2CSA domains has correlated with gra-
vidity, including DBLpam1, DBLpam3, and DBLe10.7,19
Antibody recognition to no single VAR2CSA domain has
been associated with absence of placental malaria.23 Our
approach differs from these studies in the use of a cell-free
E. coli system, the coupling of consecutive VAR2CSA
domains to account for domain–domain interactions that may
contribute to immune recognition, and sampling from a diverse
set of malaria-exposed subjects, including different ages, sexes,
and gravidities. The high throughput capacity of a protein
microarray further strengthens this multidomain approach to
understanding the development of VAR2CSA immunity.
Seroreactivity studies of VAR2CSA have typically com-
pared serum results from pregnant women. Women included
in this study were not pregnant at the time of serum collec-
tion, but antibody responses to VAR2CSA were nonetheless
robust. However, this difference in serum sampling may
Figure 3. Average fluorescence intensities of subjects for each VAR2CSA fragment. Values are reported as means with standard errors.
*P < 0.05; **P < 0.01. Two-sample Kolmogorov–Smirnov test.
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account for some discrepancies with results from previous
studies if, for example, transient rises in antibody levels to
particular VAR2CSA domains occur during pregnancy. A
limitation of this study is that some VAR2CSA domains may
not have been folded correctly with the protein expression
system used. This may have been the case with Fragment 3,
a fragment for which there was no significant seroreactivity,
suggesting that it may not have been expressed appropri-
ately, particularly given that previous work has found that
the two VAR2CSA domains included in this fragment,
DBLpam3 and DBLpam4, were seroreactive in multigravid
east African women.7
Fragments 1 and 2 were recognized significantly more in
adults than in children, but not significantly more in women
with at least one pregnancy. This suggests that greater malaria
exposure leads to increased recognition of these two fragments,
possibly due to their similarity to other malaria antigens or to
a secondary, as yet undetermined role of VAR2CSA in which
specific VAR2CSA regions within these fragments are exposed
to the immune system. Both Fragments 1 and 2 contained
most of the minimal CSA-binding region ID1-DBL2pam-
ID2a. A recent Cameroon study also found that seroreactivity
to the CSA-binding region was not associated with gravid-
ity.24 Indeed, Cameroonian men reacted just as much to this
region as did Cameroonian women, suggesting an association
with malaria exposure similar to our findings.
Other studies investigating PfEMP1 seroreactivity have used
small segments, typically less than 300 amino acids, of single
domains such as the first DBL-alpha domain.25–27 These small
fragments may fail to react with antibodies that bind to discon-
tinuous epitopes contained outside their boundaries. Here, we
cloned domains as overlapping pairs and observed a high level
of reactivity against these larger fragments. This approach is
inclusive of interdomain and discontinuous epitopes that may
improve sensitivity. A subtractive approach can then be used
to map the actual antibody binding sites.
Although expression of the entire VAR2CSA extracellular
region may be impractical for vaccine development, our find-
ings suggest that focusing efforts on the last three constitutive
extracellular domains may produce seroreactivity similar to
that observed in multigravid women from a malaria-endemic
region. This contrasts with current pregnancy-associated
malaria vaccine development efforts that have focused on the
first four extracellular VAR2CSA domains, given their role
in CSA binding.8–10 In addition, expression of consecutive
VAR2CSA domains may produce seroreactivity results that
more accurately reflect acquisition of natural immunity than
single VAR2CSA domains alone.
Protein microarrays are a powerful tool to identify PfEMP1
domains uniquely seroreactive to multigravid women in
malaria-endemic regions, thus shedding further light on the
acquisition of natural immunity to pregnancy-associated
malaria. Microarrays have been successfully populated with
multiple PfEMP1 variants17 and field variants of other
malaria vaccine candidate antigens.28 Our next step is to
develop a microarray with fragments from multiple, diverse
VAR2CSA variants derived from laboratory strains and field
isolates that can be probed with serum samples from malaria-
endemic regions, particularly from longitudinal studies that
include pregnant women, to understand the role of VAR2CSA
diversity in protective immunity. We will compare sero-
reactivity of individual VAR2CSA domains versus coupled
consecutive domains to determine which fragments best
reflect the development of protective immunity and compare
results to current pregnancy-associated malaria vaccine can-
didates, including variants of the minimal CSA-binding region
ID1-DBL2pam-ID2a. VAR2CSA field variants will be an
important component of this second generation array, given
the extraordinary genetic diversity of var genes,14 which may
not be adequately represented in laboratory strains. This
approach may provide additional insight into the develop-
ment of pregnancy-associated antimalarial immunity and the
need for multiple VAR2CSA domain targets for a vaccine
that would potentially be efficacious against pregnancy-
associated malaria in diverse geographic regions.
Received August 21, 2014. Accepted for publication March 3, 2015.
Published online April 27, 2015.
Acknowledgments: We thank Danzele Coulibaly, Sekouba Mariko,
and Moctar Traore for administrative support; Nicole Eddington
Johnson and Amanda Icenroad for technical and administrative sup-
port; the team of the Bandiagara Malaria Project in Bandiagara for
their dedication; and the community of Bandiagara, Mali.
Financial support: This work was supported by the Howard Hughes
Medical Institute; a cooperative agreement (U19AI065683) from the
National Institute of Allergy and Infectious Diseases; U.S. National
Institutes of Health grants R44AI066791, U19AI089686, R01AI095916,
and R01AI093635; a training grant (D43TW001589) from the Fogarty
International Center of the U.S. National Institutes of Health; and a
Burroughs Wellcome Fund/American Society of Tropical Medicine
and Hygiene Postdoctoral Fellowship to Mark A. Travassos. J.
Alexandra Rowe was supported by the Wellcome Trust (grant 084226).
Shannon Takala-Harrison was supported by NIH R01AI101713.
Authors’ addresses: Mark A. Travassos, Jason A. Bailey, Matthew
Adams, Myaing M. Nyunt, Amed Ouattara, Kirsten E. Lyke, Matthew
B. Laurens, Andrea A. Berry, Shannon Takala-Harrison, Miriam K.
Laufer, and Christopher V. Plowe, Howard Hughes Medical Institute/
Center for Vaccine Development, University of Maryland School of
Medicine, Baltimore, MD, E-mails: mtravass@medicine.umaryland.edu,
jbail006@umaryland.edu, madams@medicine.umaryland.edu, mnyunt@
medicine.umaryland.edu, aouattara@medicine.umaryland.edu, klyke@
medicine.umaryland.edu, mlaurens@medicine.umaryland.edu, aberry@
medicine.umaryland.edu, stakala@medicine.umaryland.edu, mlaufer@
medicine.umaryland.edu, and cplowe@medicine.umaryland.edu. Drissa
Coulibaly, Amadou Niangaly, Abdoulaye K. Kone, Bourema Kouriba,
Ogobara K. Doumbo, and Mahamadou A. Thera, Malaria Research
and Training Center, University of Sciences, Techniques and Tech-
nology, Bamako, Mali, E-mails: coulibalyd@icermali.org, niangaly@
icermali.org, akkone@yahoo.fr, kouriba@icermali.org, okd@icermali
.org, and mthera@icermali.org. Jozelyn Pablo, Algis Jasinskas, Rie
Nakajima, and Philip L. Felgner, Division of Infectious Diseases,
Department ofMedicine, University of California, Irvine, CA, E-mails:
jozelynp@gmail.com, ajasinsk@uci.edu, nakajimr@gmail.com, and
pfelgner@uci.edu. J. Alexandra Rowe, Centre for Immunity, Infection
and Evolution, Institute of Immunology and Infection Research,
School of Biological Sciences, University of Edinburgh, Edinburgh,
United Kingdom, E-mail: alex.rowe@ed.ac.uk.
This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the
original author and source are credited.
REFERENCES
1. Rowe JA, Claessens A, Corrigan RA, Arman M, 2009. Adhesion
of Plasmodium falciparum-infected erythrocytes to human
cells: molecular mechanisms and therapeutic implications.
Expert Rev Mol Med 11: e16.
2. Fried M, Duffy PE, 1996. Adherence of Plasmodium falciparum
to chondroitin sulfate A in the human placenta. Science 272:
1502–1504.
SEROEPIDEMIOLOGY OF VAR2CSA RECOGNITION IN MALIAN SERA 1193
3. Salanti A, Staalsoe T, Lavstsen T, Jensen AT, Sowa MP, Arnot
DE, Hviid L, Theander TG, 2003. Selective upregulation of
a single distinctly structured var gene in chondroitin sulphate
A-adhering Plasmodium falciparum involved in pregnancy-
associated malaria.Mol Microbiol 49: 179–191.
4. Salanti A, Dahlback M, Turner L, Nielsen MA, Barfod L,
Magistrado P, Jensen AT, Lavstsen T, Ofori MF, Marsh K,
Hviid L, Theander TG, 2004. Evidence for the involvement
of VAR2CSA in pregnancy-associated malaria. J Exp Med
200: 1197–1203.
5. Duffy PE, Fried M, 2003. Antibodies that inhibit Plasmodium
falciparum adhesion to chondroitin sulfate A are associated
with increased birth weight and the gestational age of newborns.
Infect Immun 71: 6620–6623.
6. Brolin KJ, Persson KE, Wahlgren M, Rogerson SJ, Chen Q, 2010.
Differential recognition of P. falciparum VAR2CSA domains
by naturally acquired antibodies in pregnant women from a
malaria endemic area. PLoS ONE 5: e9230.
7. Oleinikov AV, Rossnagle E, Francis S, Mutabingwa TK, Fried M,
Duffy PE, 2007. Effects of sex, parity, and sequence variation on
seroreactivity to candidate pregnancy malaria vaccine antigens.
J Infect Dis 196: 155–164.
8. Bordbar B, Tuikue-Ndam N, Bigey P, Doritchamou J, Scherman
D, Deloron P, 2012. Identification of Id1-DBL2X of VAR2CSA
as a key domain inducing highly inhibitory and cross-reactive
antibodies. Vaccine 30: 1343–1348.
9. Clausen TM, Christoffersen S, Dahlback M, Langkilde AE,
Jensen KE, Resende M, Agerbaek MO, Andersen D, Berisha
B, Ditlev SB, Pinto VV, Nielsen MA, Theander TG, Larsen S,
Salanti A, 2012. Structural and functional insight into how the
Plasmodium falciparum VAR2CSA protein mediates binding
to chondroitin sulfate A in placental malaria. J Biol Chem 287:
23332–23345.
10. Srivastava A, Gangnard S, Dechavanne S, Amirat F, Lewit BA,
Bentley GA, Gamain B, 2011. Var2CSA minimal CSA binding
region is located within the N-terminal region. PLoS ONE
6: e20270.
11. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I,
Dicko A, Diemert DJ, Heppner DG Jr, Stewart VA, Angov
E, Soisson L, Leach A, Tucker K, Lyke KE, Plowe CV, 2006.
Safety and allele-specific immunogenicity of a malaria vaccine
in Malian adults: results of a phase I randomized trial. PLoS
Clin Trials 1: e34.
12. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Kone AK,
Guindo AB, Traore K, Dicko A, Sagara I, Sissoko MS, Baby
M, Sissoko M, Diarra I, Niangaly A, Dolo A, Daou M,
Diawara SI, Heppner DG, Stewart VA, Angov E, Bergmann-
Leitner ES, Lanar DE, Dutta S, Soisson L, Diggs CL, Leach A,
Owusu A, Dubois MC, Cohen J, Nixon JN, Gregson A, Takala
SL, Lyke KE, Plowe CV, 2008. Safety and immunogenicity of
an AMA-1 malaria vaccine in Malian adults: results of a phase 1
randomized controlled trial. PLoS ONE 3: e1465.
13. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara
A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B,
Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS,
Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y,
Blackwelder WC, Godeaux O, Vekemans J, Dubois MC,
Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs
CL, House B, Lanar DE, Dutta S, Heppner DG Jr, Plowe CV,
2011. A field trial to assess a blood-stage malaria vaccine.
N Engl J Med 365: 1004–1013.
14. Rask TS, Hansen DA, Theander TG, Gorm PA, Lavstsen T,
2010. Plasmodium falciparum erythrocyte membrane protein 1
diversity in seven genomes—divide and conquer. PLOS
Comput Biol 6: pii.e1000933.
15. Davies DH, Liang X, Hernandez JE, Randall A, Hirst S, Mu Y,
Romero KM, Nguyen TT, Kalantari-Dehaghi M, Crotty S,
Baldi P, Villarreal LP, Felgner PL, 2005. Profiling the humoral
immune response to infection by using proteome microarrays:
high-throughput vaccine and diagnostic antigen discovery.
Proc Natl Acad Sci USA 102: 547–552.
16. Doolan DL, Mu Y, Unal B, Sundaresh S, Hirst S, Valdez C,
Randall A, Molina D, Liang X, Freilich DA, Oloo JA, Blair
PL, Aguiar JC, Baldi P, Davies DH, Felgner PL, 2008. Profil-
ing humoral immune responses to P. falciparum infection with
protein microarrays. Proteomics 8: 4680–4694.
17. Travassos MA, Niangaly A, Bailey JA, Ouattara A, Coulibaly D,
Laurens MB, Pablo J, Jasinskas A, Nakajima-Sasaki R, Berry
AA, Takala-Harrison S, Kouriba B, Rowe JA, Lyke KE,
Doumbo OK, Thera MA, Felgner PL, Plowe CV, 2013.
Seroreactivity to Plasmodium falciparum erythrocyte mem-
brane protein 1 intracellular domain in malaria-exposed chil-
dren and adults. J Infect Dis 208: 1514–1519.
18. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A,
Weiss GE, Molina DM, Burk CR, Waisberg M, Jasinskas A,
Tan X, Doumbo S, Doumtabe D, Kone Y, Narum DL, Liang
X, Doumbo OK, Miller LH, Doolan DL, Baldi P, Felgner
PL, Pierce SK, 2010. A prospective analysis of the Ab
response to Plasmodium falciparum before and after a malaria
season by protein microarray. Proc Natl Acad Sci USA 107:
6958–6963.
19. Tuikue Ndam NG, Salanti A, Le-Hesran JY, Cottrell G, Fievet N,
Turner L, Sow S, Dangou JM, Theander T, Deloron P, 2006.
Dynamics of anti-VAR2CSA immunoglobulin G response
in a cohort of Senegalese pregnant women. J Infect Dis 193:
713–720.
20. Brolin KJ, Persson KE, Wahlgren M, Rogerson SJ, Chen Q, 2010.
Differential recognition of P. falciparum VAR2CSA domains
by naturally acquired antibodies in pregnant women from a
malaria endemic area. PLoS ONE 5: e9230.
21. Oleinikov AV, Voronkova VV, Frye IT, Amos E, Morrison R,
Fried M, Duffy PE, 2012. A plasma survey using 38 PfEMP1
domains reveals frequent recognition of the Plasmodium
falciparum antigen VAR2CSA among young Tanzanian chil-
dren. PLoS ONE 7: e31011.
22. Gnidehou S, Doritchamou J, Arango EM, Cabrera A, Arroyo
MI, Kain KC, Ndam NT, Maestre A, Yanow SK, 2014. Func-
tional antibodies against VAR2CSA in nonpregnant popula-
tions from Colombia exposed to Plasmodium falciparum and
Plasmodium vivax. Infect Immun 82: 2565–2573.
23. Tutterrow YL, Avril M, Singh K, Long CA, Leke RJ, Sama G,
Salanti A, Smith JD, Leke RG, Taylor DW, 2012. High levels
of antibodies to multiple domains and strains of VAR2CSA
correlate with the absence of placental malaria in Cameroonian
women living in an area of high Plasmodium falciparum trans-
mission. Infect Immun 80: 1479–1490.
24. Babakhanyan A, Leke RG, Salanti A, Bobbili N, Gwanmesia P,
Leke RJ, Quakyi IA, Chen JJ, Taylor DW, 2014. The antibody
response of pregnant Cameroonian women to VAR2CSA
ID1-ID2a, a small recombinant protein containing the CSA-
binding site. PLoS ONE 9: e88173.
25. Barry AE, Trieu A, Fowkes FJ, Pablo J, Kalantari-Dehaghi M,
Jasinskas A, Tan X, Kayala MA, Tavul L, Siba PM, Day KP,
Baldi P, Felgner PL, Doolan DL, 2011. The stability and com-
plexity of antibody responses to the major surface antigen of
Plasmodium falciparum are associated with age in a malaria
endemic area.Mol Cell Proteomics 10:M111.008326.
26. Mayor A, Rovira-Vallbona E, Srivastava A, Sharma SK, Pati
SS, Puyol L, Quinto L, Bassat Q, Machevo S, Mandomando
I, Chauhan VS, Alonso PL, Chitnis CE, 2009. Functional
and immunological characterization of a Duffy binding-like
alpha domain from Plasmodium falciparum erythrocyte
membrane protein 1 that mediates rosetting. Infect Immun
77: 3857–3863.
27. Oguariri RM, Borrmann S, Klinkert MQ, Kremsner PG, Kun JF,
2001. High prevalence of human antibodies to recombinant
Duffy binding-like alpha domains of the Plasmodium falciparum-
infected erythrocyte membrane protein 1 in semi-immune
adults compared to that in nonimmune children. Infect Immun
69: 7603–7609.
28. Bailey JA, Pablo J, Niangaly A, Travassos MA, Ouattara A,
Coulibaly D, Laurens MB, Takala-Harrison SL, Lyke KE,
Skinner J, Berry AA, Jasinskas A, Nakajima-Sasaki R,
Kouriba B, Thera MA, Felgner PL, Doumbo OK, Plowe
CV, 2015. Seroreactivity to a large panel of field-derived Plas-
modium falciparum blood stage antigen variants reflects sea-
sonal and lifetime acquired immunity to malaria. Am J Trop
Med Hyg 92: 9–12.
1194 TRAVASSOS AND OTHERS
